Abstract: DOI: 10.2478/cipms-2022-0020 Curr. Issues Pharm. Med. Sci., Vol. 35, No. 3, Pages 106-110 Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/ Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19 Hayder Assad Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kufa, Najaf, Iraq ARTICLE INFO Received 08 October 2021 Accepted 10 June 2022 Keywords: COVID-19, hospitalized patients, medications, mortality rate. ABSTRACT There are many treatment modalities for COVID-19 – with varied outcome. Therefore, authors designed this study to assess prescribing patterns and the clinical outcome for hospitalized patients with severe and critical COVID-19 so as to determine the most effective approach. Authors conducted a retrospective observational study on 346 adult patients with either severe or critical COVID-19, who were admitted to public hospitals in Al-Najaf city, Iraq from June to September 2020. Patients' information, medications and outcomes were collected from their medical records in the registered office of the hospital. A total of 346 patients were enrolled, with a majority of patients being adults above 35 years old and male (70.2%). Most patients (81%) received corticosteroid as dexamethasone, and about 45% of all patients were given convalescent plasma therapy, while a few patients were prescribed antiviral favipiravir (23%) and lopinavir/ritonavir (19%). As supportive care medications, anticoagulant such as enoxaparin was administered to most of the patients (93%) and more than half of all patients received the broad-spectrum antibiotic, meropenem. The majority of the patients recovered and were discharged alive (66%), however, the inhospital mortality rate was 26%. Interestingly, patients treated with enoxaparin alone or in combination with hydroxychloroquine were associated with better outcome. The prescribing pattern of COVID-19 specific medications and supportive care is aligned with guideline recommendations and associated with a beneficial therapeutic outcome.